Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The overall goal of this exploratory proof-of-concept study is to determine whether, in
participants with pulmonary tuberculosis caused by M. tuberculosis (MTB) with or without
rifampin resistance-conferring rpoB-gene mutations, the combination of meropenem and
amoxicillin/clavulanate with rifampin has greater early bactericidal activity (EBA) than the
combination of meropenem and amoxicillin/clavulanate without rifampin. Funding Source- FDA
OOPD.